Latest From Cerus Corp.
While a panel of US FDA experts agreed that pathogen reduction technology is a promising strategy for reducing blood platelet contaminations, they raised concerns about the cost of implementing the technology. The maker of the technology, Cerus, says the panel was under-briefed and distracted.
Emergency funding to battle the summer's mosquito-borne Zika threat is trapped in a military/VA spending bill. Conferees must find a compromise between the House's $622m bid and the Senate's $1.1b offer in the thin stretch of time when both chambers will be session before they adjourn on July 15. In the interim, FDA has authorized more Zika tests.
Device industry news on Dec. 2 includes an IDE approval to study a super-small neurostimulator to treat face pain; distribution agreements in diabetes and blood processing; a product approval; and new legislation focused on telemedicine.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced January-February 2015.
- Infection Control-Sterilization
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Cerus Corp.
- Senior Management
William M Greenman, Pres. & CEO
Kevin D Green, VP, Fin. & CFO
Laurence M Corash, MD, CSO
Richard J Benjamin, PhD, CMO
- Contact Info
Phone: (925) 288-6000
2550 Stanwell Dr.
Concord, CA 94520
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.